Twenty-fraction cervical chemoradiation shortened treatment but raised a late GI toxicity signal
44 Gy in 20 fractions shortened cervical cancer treatment by seven days but showed numerically more severe late GI toxicity.
Tag
cervical
Rectal retractors reduced rectal dose but increased bladder dose in cervical brachytherapy
Rectal retractor use lowered rectal D2cc and was associated with fewer grade ≥2 vaginal adverse events without reducing target coverage.
PTSD symptom burden affected 29% after cervical cancer HDR brachytherapy
Nearly three in ten surveyed cervical cancer survivors reported partial-to-probable PTSD symptoms several years after HDR brachytherapy.
MRI improved LLM-based recurrence prediction after definitive cervical chemoradiotherapy
Multimodal LLM prediction reached an AUC of 0.79, but AI-generated MRI reports showed clinically important discordances requiring expert review.
RTT-led online adaptive radiotherapy maintained cervical target coverage in 33-minute sessions
Across 744 cervical oART fractions, RTT-led adaptation took a median 33 minutes while maintaining ≥95% target D98 in every fraction.
Centralized MR-guided brachytherapy maintained 95% local control in cervical cancer
Nationwide referral to one MR-IGABT centre kept median treatment time at 50 days and achieved 95% 3-year local control.
TIMELESS–SIRT1–Ku70 signaling promoted NHEJ-mediated radioresistance in cervical cancer models
TIMELESS scaffolded SIRT1-mediated Ku70 deacetylation, enhanced NHEJ repair and increased radioresistance in cervical cancer cells and xenografts.
One-week HDR brachytherapy shortened cervical cancer treatment without higher reported toxicity
Compressing three HDR brachytherapy fractions into one week shortened overall treatment time and increased early complete response without improving survival.
Ovary–PTV distance defined where ovarian dose prediction became unreliable
Random forest best predicted ovarian dose after transposition, but all models deteriorated sharply when ovaries lay within approximately 17 mm of the PTV.
CT-based cervical brachytherapy achieved 84% five-year local control
Routine CT-based adaptive brachytherapy achieved 84.4% five-year local control despite 56.9% of patients having stage III–IV cervical cancer.
Definitive pelvic radiotherapy was associated with longer survival in stage IVB cervical cancer
Median survival was 25 versus 18 months with chemotherapy plus definitive pelvic radiotherapy after propensity matching in stage IVB cervical cancer.
Sexual inactivity and dyspareunia remained common after cervical radio(chemo)therapy
Sexual inactivity reached 49% and dyspareunia 54% after cervical radio(chemo)therapy, with fatigue central to broader survivorship impairment.
DWI/ADC changed residual cervical tumor geometry before brachytherapy despite similar overall volumes
Adding DWI/ADC produced substantially different residual GTV geometry before cervical brachytherapy, with a median Dice overlap of only 0.33.
Multimodal AI predicted radiation proctitis across different CT devices with 0.865 AUC
Combined radiomics, foundation-model and clinical features predicted grade ≥2 radiation proctitis with 0.865 AUC on an independent imaging device.
Cervical cancer advanced by one stage approximately every 8.6 weeks before radiotherapy
Cervical cancer stage progression was estimated every 8.6 weeks of treatment delay and was faster among women living with HIV.